These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1836917)

  • 21. Drugs for vomiting caused by cancer chemotherapy.
    Med Lett Drugs Ther; 1993 Dec; 35(912):124-6. PubMed ID: 8264505
    [No Abstract]   [Full Text] [Related]  

  • 22. [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
    Zeng W; Zhou J; Zhang P
    Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):294-7. PubMed ID: 7587900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
    Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
    Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
    Reilly RT
    IDrugs; 2004 Jan; 7(1):64-9. PubMed ID: 14730469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
    White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
    Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD
    Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
    Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA
    Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study].
    Golaszewski T; Kölbl H; Lahousen M; Staab HJ
    Wien Klin Wochenschr; 1995; 107(20):613-21. PubMed ID: 7502509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral ondansetron for preventing nausea and vomiting.
    Cooke CE; Mehra IV
    Am J Hosp Pharm; 1994 Mar; 51(6):762-71. PubMed ID: 8010314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ondansetron in the treatment of theophylline overdose.
    Brown SG; Prentice DA
    Med J Aust; 1992 Apr; 156(7):512. PubMed ID: 1532627
    [No Abstract]   [Full Text] [Related]  

  • 34. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of delayed emesis caused by chemotherapy.
    Harmon D; O'Brien B
    N Engl J Med; 2000 Sep; 343(12):889; author reply 889-90. PubMed ID: 11001695
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Archimedes. Question 1. Does oral ondansetron reduce vomiting and the need for intravenous fluids and hospital admission in children presenting with vomiting secondary to gastroenteritis?
    Howard S
    Arch Dis Child; 2010 Nov; 95(11):945-7. PubMed ID: 20980278
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent antiemetic effects of the new serotonin antagonists.
    Ryan KP; Evans JS
    West J Med; 1992 Jan; 156(1):67. PubMed ID: 1531161
    [No Abstract]   [Full Text] [Related]  

  • 40. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.